Table 2.
Comparison of the mucocutaneous adverse effects to Covishield vs Covaxin
| Parameters | Vaccine administered | |
|---|---|---|
|
| ||
| Covishield (n=326) | Covaxin (n=117) | |
| Number of doses of vaccine taken | ||
| One | 46 (17.2) | 47 (40.2) |
| Two | 270 (82.8) | 70 (59.8) |
| Mucocutaneous lesions appeared after | ||
| 1st dose | 47 (14.4) | 20 (17.1) |
| 2nd dose | 6 (1.9) | 2 (1.7) |
| Both doses | 8 (2.4) | 4 (3.4) |
| None | 265 (81.3) | 91 (77.8) |
| Onset of mucocutaneous lesions post-vaccination | ||
| <1 h | 2 (0.6) | 0 (0) |
| 1-24 h | 33 (10.1) | 11 (9.4) |
| >24-72 h | 9 (2.8) | 7 (6) |
| 4-7 days | 10 (3.1) | 4 (3.4) |
| >7 days | 7 (2.1) | 4 (3.4) |
| Not applicable | 265 (81.3) | 91 (77.8) |
| Duration/persistence of mucocutaneous lesions | ||
| <1 h | 0 (0) | 0 (0) |
| 1-24 h | 7 (2.1) | 9 (7.7) |
| >24-72 h | 19 (5.9) | 3 (2.6) |
| 4-7 days | 10 (3.1) | 1 (0.8) |
| >7 days | 25 (7.6) | 13 (11.1) |
| Not applicable | 265 (81.3) | 91 (77.8) |
| Symptom* | ||
| Pain | 39 (11.8) | 22 (18.8) |
| Pruritus | 33 (10.1) | 13 (11.1) |
| Swelling | 31 (9.5) | 9 (7.7) |
| Erythema | 17 (5.2) | 8 (6.8) |
| Burning sensation | 18 (5.5) | 9 (7.7) |
| Scaling | 7 (2.1) | 1 (0.8) |
| Pigmentation | 4 (1.2) | 3 (2.6) |
| Tingling | 2 (0.6) | 1 (0.8) |
| Gum bleeding | 2 (0.6) | 0 (0) |
| Ecchymosis | 1 (0.3) | 1 (0.8) |
| None | 265 (81.3) | 91 (77.8) |
| Mucocutaneous findings* | ||
| Local injection site reaction | 46 (17.2) | 21 (18) |
| Urticarial rash | 19 (5.9) | 10 (8.5) |
| Aggravation of preexisting dermatoses^ | 7 (2.1) | 4 (3.4) |
| Morbilliform rash | 4 (1.2) | 3 (2.6) |
| Apthous ulcer | 7 (2.1) | 0 (0) |
| Pityriasis rosea like eruption | 5 (1.5) | 1 (0.8) |
| Telogen effluvium | 6 (1.9) | 0 (0) |
| Herpes zoster | 5 (1.5) | 0 (0) |
| Purpuric rash | 3 (0.9) | 1 (0.8) |
| Erythema multiforme | 3 (0.9) | 0 (0) |
| Ulceration | 2 (0.6) | 0 (0) |
| Vasculitis | 1 (0.3) | 1 (0.8) |
| Cellulitis | 2 (0.6) | 0 (0) |
| Lichen planus | 2 (0.6) | 0 (0) |
| Alopecia areata | 2 (0.6) | 0 (0) |
| Hyperpigmentation | 0 (0) | 1 (0.8) |
| Vesicular rash | 1 (0.3) | 0 (0) |
| None | 265 (81.3) | 91 (77.8) |
| Systemic manifestations* | ||
| Malaise | 235 (72.1) | 86 (73.5) |
| Fever | 174 (53.4) | 55 (47) |
| Headache | 102 (31.3) | 23 (19.9) |
| Joint pain | 30 (9.2) | 12 (10.3) |
| Chills | 31 (9.5) | 6 (5.1) |
| Nausea | 15 (4.6) | 0 (0) |
| Vomiting | 11 (3.4) | 4 (3.4) |
| Diarrhoea | 6 (1.9) | 4 (3.4) |
| Anaphylaxis | 3 (0.9) | 0 (0) |
| Consultation sought # | ||
| Dermatologist | 39 (11.8) | 22 (18.8) |
| Specialist (non-dermatologist) | 6 (1.9) | 1 (0.8) |
| General physician | 16 (5) | 3 (2.6) |
| Not applicable | 265 (81.3) | 91 (77.8) |
| Mode of consultation # | ||
| Telemedicine In-person | 45 (13.7) 16 (5) | 21 (18) 5 (4.2) |
| Not applicable | 265 (81.3) | 91 (77.8) |
| Place of consultation # | ||
| Government set-up | 28 (8.6) | 3 (2.6) |
| Private establishment | 33 (10.1) | 23 (19.6) |
| Not applicable | 265 (81.3) | 91 (77.8) |
| Outcome # | ||
| Recovery with symptomatic treatment | 22 (6.7) | 15 (12.8) |
| Recovery without any treatment | 38 (11.7) | 11 (9.4) |
| Hospitalization | 1 (0.3) | 0 (0) |
| Not applicable | 265 (81.3) | 91 (77.8) |
*Multiple responses considered. ^ Aggravation of pre-existing dermatoses included urticaria-8 (Covishield-4, Covaxin-4), psoriasis-1 (Covishield), vitiligo-1 (Covishield), and lichen planus-1 (Covishield). # Responses with mucocutaneous reactions only considered